We use cookies to make your experience better. To comply with the new e-Privacy directive, we need to ask for your consent to set the cookies. Learn more.
Cell Signaling Ctla-4 (D4e9i) Rabbit mAb
List Price
$342.39
Your Price
$342.39
Cell Signaling Ctla-4 (D4e9i) Rabbit mAb - CSIG (Additional S&H or Hazmat Fees May Apply)
NETA PART:
CSIG-15119S
MFG.PART:
15119S
UNSPSC:
41116124
Manufacturer:
Cell Signaling


Size | 100 µl |
Reactivity | H |
Sensitivity | Endogenous |
Molecular Weight (kDa) | 30 |
Source/Isotype | Rabbit IgG |
Application/Dilution | {Flow Cytometry (Fixed/Permeabilized): 1:200, Flow Cytometry (Live): 1:200} |
Storage | Supplied in 10 mM sodium HEPES (pH 7.5), 150 mM NaCl, 100 µg/ml BSA, 50% glycerol and less than 0.02% sodium azide. Store at –20°C. Do not aliquot the antibody. |
Specificity/Sensitivity | CTLA-4 (D4E9I) Rabbit mAb recognizes endogenous levels of total CTLA-4 protein. |
Species Reactivity | Human |
Source/Purification | Monoclonal antibody is produced by immunizing animals with a synthetic peptide corresponding to residues surrounding Asp100 of human CTLA-4 protein. |
Background | Cytotoxic T-lymphocyte protein 4 (CTLA-4, CD152) is an Ig superfamily member that negatively regulates early T cell activation (1-4). The CTLA-4 protein is primarily expressed on T cells, including CD8+ cytotoxic T cells, CD4+ helper T cells, and CD4+/FoxP3+ regulatory T cells (1,2). CTLA-4 protein competes with CD28 for B7.1 (CD80) and B7.2 (CD86) binding at the cell surface, which results in the downregulation of T cell activity (5). The activation of SHP-2 and PP2A downstream of CTLA-4 attenuates TCR signaling (6). Research studies indicate that CTLA4 knockout mice display lymphoproliferative disorders leading to early death, confirming the role of CTLA-4 as a negative regulator of T cells (7). Mutations in the corresponding CTLA4 gene are associated with multiple disorders, including insulin-dependent diabetes mellitus, Graves disease, Hashimoto thyroiditis, celiac disease, systemic lupus erythematosus, and type V autoimmune lymphoproliferative syndrome (8,9). Additional studies demonstrate that CTLA-4 blockade is an effective strategy for tumor immunotherapy (10-12). |
SKU | CSIG-15119S |
---|---|
Supplier Part Number | 15119S |
UM | EA |
UNSPSC | 41116124 |
Manufacturer | Cell Signaling |
MSDS URL | Click here |
Temperature | -20C |
CountryOfOrigin | United States |
ProductLine | CSIG |
Qty | 1 |
MinOrderQty | 1 |
Weight | 7.000000 |
Lead Time | 5 |
Hazardous | N |